Business Summary
Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics across three therapeutic areas: Hematology, Oncology, and Inflammation & Autoimmunity (IAI). Headquartered in Wilmington, Delaware, with major operations in Switzerland, Japan, and Canada, Incyte markets its own specialty products directly in the United States while licensing rights to partners (Novartis, Eli Lilly) for ex-US commercialization of certain assets. As of December 31, 2025, the company had six commercialized compounds in the US, three in Europe, and one in Japan, backed by a growing pipeline of novel kinase inhibitors, monoclonal antibodies, and bispecific molecules.
Products & Services
- JAKAFI (ruxolitinib) — JAK1/JAK2 inhibitor; FDA-approved for myelofibrosis (MF), polycythemia vera (PV), and acute/chronic graft-versus-host disease (GVHD); primary US revenue driver; licensed to Novartis (JAKAVI) outside the US
- OPZELURA (ruxolitinib cream) — Topical JAK1/JAK2 inhibitor; FDA-approved for atopic dermatitis (AD, ages...
AI-generated summary of Item 1 (Business) from the 10-K filed Feb 10, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q2 2026| Largest holders | Reported value |
|---|---|
| BAKER BROS ADVISORS LP | $3.5B |
| BlackRock Inc | $2.0B |
| Dodge & Cox | $1.4B |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.2B |
| STATE STREET CORPORATION | $1.1B |
Annual results · 10-K
Fiscal 2025- Revenue
- $5.1B
- Net income
- $1.3B
As reported in the fiscal 2025 annual report.
Funds & ETFs · N-PORT
800 funds| Fund | Value | % of fund |
|---|---|---|
| Dodge & Cox Stock Fund | $901.6M | 0.76% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI | $611.1M | 0.03% |
| VANGUARD 500 INDEX FUND VOO | $492.8M | 0.03% |
| VANGUARD SMALL-CAP INDEX FUND VB | $441.5M | 0.23% |
| VANGUARD HEALTH CARE FUND | $285.2M | 0.75% |
| Fidelity 500 Index Fund | $268.4M | 0.03% |
| iShares Core S&P 500 ETF IVV | $261.8M | 0.03% |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VBK | $254.6M | 0.54% |
| Invesco S&P 500 Equal Weight ETF RSP | $211.3M | 0.22% |
| iShares Biotechnology ETF IBB | $159.0M | 1.75% |
800 funds reported holding $8.0B in total on their latest public Form N-PORT reports, the most recent dated September 2026. Security record
Insider trades · Form 4
Latest filings
- Pablo J Cagnoni 2026-10-19 Sell
- Lee Heeson 2026-10-05 -
- Baker Bros. Advisors LP 2026-10-02 Award
- Paul J Clancy 2026-10-02 Award
- Edmund Harrigan 2026-10-02 Award
5%+ holders · 13D/G
5 filers| Filer | % of class | Filed |
|---|---|---|
| Dodge & Cox 13G | 6.2% | 2026-05-14 |
| BAKER BROS ADVISORS LP 13D | 15.6% | 2026-05-11 |
| VANGUARD CAPITAL MANAGEMENT LLC 13G | 6.3% | 2026-04-30 |
| STATE STREET CORPORATION 13G | 5.0% | 2025-11-10 |
| BlackRock Inc 13G | 7.8% | 2025-10-17 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.
Federal lobbying · LD-2
Securities
| CUSIP | Security | Type |
|---|---|---|
| 45337C102 | INCY INCYTE PHARMACEUTICALS INC | Common stock |
| 45337CAM4 | INCY 0.375 11/15/18 INCYTE CORP | Bond |
| 45337CAN2 | INCY 1.25 11/15/20 INCYTE CORP | Bond |
| 45337CAF9 | INCY 3.5 02/15/11 * INCYTE CORP LTD | Bond |
| 45337CAJ1 | INCY 4.75 10/01/15 INCYTE CORP LTD | Bond |
| 45337CAC6 | INCY 5.5 02/01/07 INCYTE GENOMICS INC | Bond |
| 45337CAA0 | INCY 5.5 02/01/07 144A INCYTE PHARMACEUTICALS INC | Bond |